APO Research
Talk to an analyst

APO RESEARCH · REPORT

Imatinib Mesylate Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Imatinib Mesylate Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

22 December 2025176 pages

Choose your research edition.

Industry ResearchImatinib Mesylate Drugs Industry Research Report 2026110 pages · $2,950 USDIndustry Growth & TrendsGlobal Imatinib Mesylate Drugs Industry Growth and Trends Forecast to 203273 pages · $3,450 USDMarket StructureGlobal Imatinib Mesylate Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032176 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Imatinib Mesylate Drugs Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Imatinib Mesylate Drugs Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Imatinib Mesylate Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Imatinib Mesylate Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Imatinib Mesylate Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Imatinib Mesylate Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Imatinib Mesylate Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Imatinib Mesylate Drugs include Novartis. among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Imatinib Mesylate Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Imatinib Mesylate Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Imatinib Mesylate Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Imatinib Mesylate Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Imatinib Mesylate Drugs Segment by Company

Novartis

Imatinib Mesylate Drugs Segment by Type

100mg

400mg

Imatinib Mesylate Drugs Segment by Application

Hospital

Pharmacy

Imatinib Mesylate Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Imatinib Mesylate Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Imatinib Mesylate Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Imatinib Mesylate Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Imatinib Mesylate Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Imatinib Mesylate Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Imatinib Mesylate Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Imatinib Mesylate Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Imatinib Mesylate Drugs Industry Trends Table 2. Imatinib Mesylate Drugs Industry Drivers Table 3. Imatinib Mesylate Drugs Industry Opportunities and Challenges Table 4. Imatinib Mesylate Drugs Industry Restraints Table 5. Global Imatinib Mesylate Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Imatinib Mesylate Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Imatinib Mesylate Drugs Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Imatinib Mesylate Drugs Sales Market Share by Manufacturers Table 9. Global Imatinib Mesylate Drugs Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Imatinib Mesylate Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Imatinib Mesylate Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Imatinib Mesylate Drugs Manufacturers, Product Type & Application Table 13. Global Imatinib Mesylate Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Imatinib Mesylate Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of 100mg Table 17. Major Manufacturers of 400mg Table 18. Global Imatinib Mesylate Drugs Sales by Type 2021 VS 2025 VS 2032 (k units) Table 19. Global Imatinib Mesylate Drugs Sales by Type (2021-2026) & (k units) Table 20. Global Imatinib Mesylate Drugs Sales by Type (2027-2032) & (k units) Table 21. Global Imatinib Mesylate Drugs Sales Market Share by Type (2021-2026) Table 22. Global Imatinib Mesylate Drugs Sales Market Share by Type (2027-2032) Table 23. Global Imatinib Mesylate Drugs Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 24. Global Imatinib Mesylate Drugs Revenue by Type (2021-2026) & (k units) Table 25. Global Imatinib Mesylate Drugs Revenue by Type (2027-2032) & (k units) Table 26. Global Imatinib Mesylate Drugs Revenue Market Share by Type (2021-2026) Table 27. Global Imatinib Mesylate Drugs Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Hospital Table 29. Major Manufacturers of Pharmacy Table 30. Global Imatinib Mesylate Drugs Sales by Application 2021 VS 2025 VS 2032 (k units) Table 31. Global Imatinib Mesylate Drugs Sales by Application (2021-2026) & (k units) Table 32. Global Imatinib Mesylate Drugs Sales by Application (2027-2032) & (k units) Table 33. Global Imatinib Mesylate Drugs Sales Market Share by Application (2021-2026) Table 34. Global Imatinib Mesylate Drugs Sales Market Share by Application (2027-2032) Table 35. Global Imatinib Mesylate Drugs Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 36. Global Imatinib Mesylate Drugs Revenue by Application (2021-2026) & (k units) Table 37. Global Imatinib Mesylate Drugs Revenue by Application (2027-2032) & (k units) Table 38. Global Imatinib Mesylate Drugs Revenue Market Share by Application (2021-2026) Table 39. Global Imatinib Mesylate Drugs Revenue Market Share by Application (2027-2032) Table 40. Global Imatinib Mesylate Drugs Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 41. Global Imatinib Mesylate Drugs Sales by Region (2021-2026) & (k units) Table 42. Global Imatinib Mesylate Drugs Sales Market Share by Region (2021-2026) Table 43. Global Imatinib Mesylate Drugs Sales Forecasted by Region (2027-2032) & (k units) Table 44. Global Imatinib Mesylate Drugs Sales Forecasted Market Share by Region (2027-2032) Table 45. North America Imatinib Mesylate Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 46. North America Imatinib Mesylate Drugs Sales by Country (2021-2026) & (k units) Table 47. North America Imatinib Mesylate Drugs Sales by Country (2027-2032) & (k units) Table 48. Europe Imatinib Mesylate Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 49. Europe Imatinib Mesylate Drugs Sales by Country (2021-2026) & (k units) Table 50. Europe Imatinib Mesylate Drugs Sales by Country (2027-2032) & (k units) Table 51. Asia Pacific Imatinib Mesylate Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 52. Asia Pacific Imatinib Mesylate Drugs Sales by Country (2021-2026) & (k units) Table 53. Asia Pacific Imatinib Mesylate Drugs Sales by Country (2027-2032) & (k units) Table 54. South America, Middle East and Africa Imatinib Mesylate Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 55. South America, Middle East and Africa Imatinib Mesylate Drugs Sales by Country (2021-2026) & (k units) Table 56. South America, Middle East and Africa Imatinib Mesylate Drugs Sales by Country (2027-2032) & (k units) Table 57. Global Imatinib Mesylate Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Imatinib Mesylate Drugs Revenue by Region (2021-2026) & (US$ Million) Table 59. Global Imatinib Mesylate Drugs Revenue by Region (2027-2032) & (US$ Million) Table 60. Global Imatinib Mesylate Drugs Revenue Market Share by Region (2021-2026) Table 61. Global Imatinib Mesylate Drugs Revenue Market Share by Region (2027-2032) Table 62. Novartis Company Information Table 63. Novartis Business Overview Table 64. Novartis Imatinib Mesylate Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. Novartis Imatinib Mesylate Drugs Product Portfolio Table 66. Novartis Recent Development Table 67. Key Raw Materials Table 68. Raw Materials Key Suppliers Table 69. Imatinib Mesylate Drugs Distributors List Table 70. Imatinib Mesylate Drugs Customers List Table 71. Research Programs/Design for This Report Table 72. Authors List of This Report Table 73. Secondary Sources Table 74. Primary Sources List of Figures Figure 1. Imatinib Mesylate Drugs Product Image Figure 2. Global Imatinib Mesylate Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Imatinib Mesylate Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Imatinib Mesylate Drugs Sales (2021-2032) & (k units) Figure 5. Global Imatinib Mesylate Drugs Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Imatinib Mesylate Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. 100mg Image Figure 9. 400mg Image Figure 10. Global Imatinib Mesylate Drugs Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 11. Global Imatinib Mesylate Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Imatinib Mesylate Drugs Sales Market Share by Type (2021-2032) Figure 13. Global Imatinib Mesylate Drugs Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 14. Global Imatinib Mesylate Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Imatinib Mesylate Drugs Revenue Market Share by Type (2021-2032) Figure 16. Hospital Image Figure 17. Pharmacy Image Figure 18. Global Imatinib Mesylate Drugs Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 19. Global Imatinib Mesylate Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 20. Global Imatinib Mesylate Drugs Sales Market Share by Application (2021-2032) Figure 21. Global Imatinib Mesylate Drugs Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 22. Global Imatinib Mesylate Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 23. Global Imatinib Mesylate Drugs Revenue Market Share by Application (2021-2032) Figure 24. North America Imatinib Mesylate Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 25. North America Imatinib Mesylate Drugs Sales Market Share by Country (2021-2032) Figure 26. U.S. Imatinib Mesylate Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 27. Canada Imatinib Mesylate Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 28. Mexico Imatinib Mesylate Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 29. Europe Imatinib Mesylate Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 30. Europe Imatinib Mesylate Drugs Sales Market Share by Country (2021-2032) Figure 31. Germany Imatinib Mesylate Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 32. France Imatinib Mesylate Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 33. U.K. Imatinib Mesylate Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 34. Italy Imatinib Mesylate Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 35. Netherlands Imatinib Mesylate Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 36. Asia Pacific Imatinib Mesylate Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 37. Asia Pacific Imatinib Mesylate Drugs Sales Market Share by Country (2021-2032) Figure 38. China Imatinib Mesylate Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 39. Japan Imatinib Mesylate Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 40. South Korea Imatinib Mesylate Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 41. Southeast Asia Imatinib Mesylate Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 42. India Imatinib Mesylate Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 43. Australia Imatinib Mesylate Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 44. South America, Middle East and Africa Imatinib Mesylate Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 45. South America, Middle East and Africa Imatinib Mesylate Drugs Sales Market Share by Country (2021-2032) Figure 46. Brazil Imatinib Mesylate Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 47. South Africa Imatinib Mesylate Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 48. Saudi Arabia Imatinib Mesylate Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 49. Turkey Imatinib Mesylate Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 50. Argentina Imatinib Mesylate Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 51. UAE Imatinib Mesylate Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 52. Egypt Imatinib Mesylate Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 53. Chile Imatinib Mesylate Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 54. Global Imatinib Mesylate Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 55. Global Imatinib Mesylate Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 56. North America Imatinib Mesylate Drugs Revenue (2021-2032) & (US$ Million) Figure 57. North America Imatinib Mesylate Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 58. Europe Imatinib Mesylate Drugs Revenue (2021-2032) & (US$ Million) Figure 59. Europe Imatinib Mesylate Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Asia-Pacific Imatinib Mesylate Drugs Revenue (2021-2032) & (US$ Million) Figure 61. Asia-Pacific Imatinib Mesylate Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. South America, Middle East and Africa Imatinib Mesylate Drugs Revenue (2021-2032) & (US$ Million) Figure 63. South America, Middle East and Africa Imatinib Mesylate Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Imatinib Mesylate Drugs Value Chain Figure 65. Manufacturing Cost Structure Figure 66. Imatinib Mesylate Drugs Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • 100mg
  • 400mg
Applications
  • Hospital
  • Pharmacy
Companies covered
  • Novartis

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Imatinib Mesylate Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Imatinib Mesylate Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Imatinib Mesylate Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Imatinib Mesylate Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Imatinib Mesylate Drugs Market Dynamics
  1. 2.1 Imatinib Mesylate Drugs Industry Trends
  2. 2.2 Imatinib Mesylate Drugs Industry Drivers
  3. 2.3 Imatinib Mesylate Drugs Industry Opportunities and Challenges
  4. 2.4 Imatinib Mesylate Drugs Industry Restraints
3 Imatinib Mesylate Drugs Market by Manufacturers
  1. 3.1 Global Imatinib Mesylate Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Imatinib Mesylate Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global Imatinib Mesylate Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Imatinib Mesylate Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Imatinib Mesylate Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Imatinib Mesylate Drugs Manufacturers, Product Type & Application
  7. 3.7 Global Imatinib Mesylate Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Imatinib Mesylate Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Imatinib Mesylate Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Imatinib Mesylate Drugs Tier 1, Tier 2, and Tier 3
4 Imatinib Mesylate Drugs Market by Type
  1. 4.1 Imatinib Mesylate Drugs Type Introduction
  2. 4.1.1 100mg
  3. 4.1.2 400mg
  4. 4.2 Global Imatinib Mesylate Drugs Sales by Type
  5. 4.2.1 Global Imatinib Mesylate Drugs Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Imatinib Mesylate Drugs Sales by Type (2021-2032)
  7. 4.2.3 Global Imatinib Mesylate Drugs Sales Market Share by Type (2021-2032)
  8. 4.3 Global Imatinib Mesylate Drugs Revenue by Type
  9. 4.3.1 Global Imatinib Mesylate Drugs Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Imatinib Mesylate Drugs Revenue by Type (2021-2032)
  11. 4.3.3 Global Imatinib Mesylate Drugs Revenue Market Share by Type (2021-2032)
5 Imatinib Mesylate Drugs Market by Application
  1. 5.1 Imatinib Mesylate Drugs Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Pharmacy
  4. 5.2 Global Imatinib Mesylate Drugs Sales by Application
  5. 5.2.1 Global Imatinib Mesylate Drugs Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Imatinib Mesylate Drugs Sales by Application (2021-2032)
  7. 5.2.3 Global Imatinib Mesylate Drugs Sales Market Share by Application (2021-2032)
  8. 5.3 Global Imatinib Mesylate Drugs Revenue by Application
  9. 5.3.1 Global Imatinib Mesylate Drugs Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Imatinib Mesylate Drugs Revenue by Application (2021-2032)
  11. 5.3.3 Global Imatinib Mesylate Drugs Revenue Market Share by Application (2021-2032)
6 Global Imatinib Mesylate Drugs Sales by Region
  1. 6.1 Global Imatinib Mesylate Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Imatinib Mesylate Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Imatinib Mesylate Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global Imatinib Mesylate Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Imatinib Mesylate Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Imatinib Mesylate Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Imatinib Mesylate Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Imatinib Mesylate Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Imatinib Mesylate Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Imatinib Mesylate Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Imatinib Mesylate Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Imatinib Mesylate Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Imatinib Mesylate Drugs Revenue by Region
  1. 7.1 Global Imatinib Mesylate Drugs Revenue by Region
  2. 7.1.1 Global Imatinib Mesylate Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Imatinib Mesylate Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global Imatinib Mesylate Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global Imatinib Mesylate Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Imatinib Mesylate Drugs Revenue (2021-2032)
  8. 7.2.2 North America Imatinib Mesylate Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Imatinib Mesylate Drugs Revenue (2021-2032)
  11. 7.3.2 Europe Imatinib Mesylate Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Imatinib Mesylate Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Imatinib Mesylate Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Imatinib Mesylate Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Imatinib Mesylate Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Novartis
  2. 8.1.1 Novartis Company Information
  3. 8.1.2 Novartis Business Overview
  4. 8.1.3 Novartis Imatinib Mesylate Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Novartis Imatinib Mesylate Drugs Product Portfolio
  6. 8.1.5 Novartis Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Imatinib Mesylate Drugs Value Chain Analysis
  2. 9.1.1 Imatinib Mesylate Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Imatinib Mesylate Drugs Production Mode & Process
  6. 9.2 Imatinib Mesylate Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Imatinib Mesylate Drugs Distributors
  9. 9.2.3 Imatinib Mesylate Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst